Journal article
The Role of High-Risk Human Papilloma Virus Testing in the Surveillance of Cervical Cancer After Treatment
Archives of pathology & laboratory medicine (1976), v 139(11), pp 1437-1440
01 Nov 2015
PMID: 26516940
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Context.-Cervical cancer affects 12 000 women in the United States annually. However, despite its prevalence, there remains no good methodology to detect its recurrence.
Objective.-To identify the role of cervicovaginal high-risk human papilloma virus (hr-HPV) testing in predicting cervical cancer recurrence.
Design.-This is a retrospective study of patients who underwent hr-HPV testing as part of their routine surveillance for cervical cancer. Standard statistical analyses, including chi(2) test and multivariable logistic regression, were performed with IBM SPSS 19.0.
Results.-A total of 133 patients were identified, of whom 107 (80%) had squamous cell carcinoma. Ninety patients (68%) had bulky disease and were treated primarily with chemoradiation and brachytherapy. Of patients whose disease recurred, 5 patients (42%) had tested positive for hr-HPV during their surveillance period, compared to 13 patients (11%) for whom disease did not recur (relative risk: 3.88, P = .002). On multivariate logistic regression, hr-HPV status remained significantly predictive of disease recurrence (odds ratio: 12.3, P = .02, 95% confidence interval: 1.5-99.6). Using 2 x 2 table analysis, we found that while cervicovaginal cytology has limited specificity (5.7%) in predicting recurrence, the combination of cytology with hr-HPV testing increases the specificity of testing to 89.3%.
Conclusions.-Persistence of hr-HPV is a risk factor for disease recurrence. High-risk-HPV testing is not routinely used during surveillance for cervical cancer, but this study suggests that large, prospective trials investigating the role of hr-HPV testing in cervical cancer surveillance are needed.
Metrics
Details
- Title
- The Role of High-Risk Human Papilloma Virus Testing in the Surveillance of Cervical Cancer After Treatment
- Creators
- Miao Crystal Yu - Magee-Womens HospitalR. Marshall Austin - University of WashingtonJeff Lin - University of PittsburghTiffany Beck - University of PittsburghSushil Beriwal - University of WashingtonJohn T. Comerci - University of PittsburghRobert P. Edwards - University of PittsburghPaniti Sukumvanich - University of PittsburghJoseph Kelley - University of PittsburghAlexander B. Olawaiye - Magee-Womens Hospital
- Publication Details
- Archives of pathology & laboratory medicine (1976), v 139(11), pp 1437-1440
- Publisher
- Coll Amer Pathologists
- Number of pages
- 4
- Grant note
- T32CA009515 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) T32 CA009515 / NCI NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000368421700014
- Scopus ID
- 2-s2.0-84945939954
- Other Identifier
- 991021897394904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Medical Laboratory Technology
- Medicine, Research & Experimental
- Pathology